Wanli Lin

Dr. Wanli Lin


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
SHShujie Huang
Shujie Huang
HWHansheng Wu
Hansheng Wu
CCChao Cheng
Chao Cheng
MZMing Zhou
Ming Zhou
EXEnwu Xu
Enwu Xu
GQGuibin Qiao
Guibin Qiao
Purpose: The present study sets out to evaluate the feasibility, safety, and effectiveness of conversion surgery following induction immunochemotherapy for patients with initially unresectable locally advanced esophageal squamous cell carcinoma (ESCC) in a real-world scenario.Materials and Methods: In this multi-center, real-world study (NCT04822103), patients who had unresectable ESCC disease were enrolled across eight medical centers in China. All patients received programmed death receptor-1 (PD-1) inhibitor plus chemotherapy every 3 weeks for at least two cycles. Patients with significant relief of cancer-related clinical symptoms and radiological responsive disease were deemed surgical candidates. Feasibility and safety profile of immunochemotherapy plus conversion surgery, radiological and pathological tumor responses, as well as short-term survival outcomes were evaluated. Moreover, data of an independent ESCC cohort receiving induction chemotherapy (iC) were compared.Results: One hundred and fifty-five patients were enrolled in the final analysis. Esophagectomy was offered to 116 patients, yielding a conversion rate of 74.8%. R0 resection rate was 94%. Among the 155 patients, 107 (69.0%) patients experienced at least one treatment-related adverse event (TRAE) and 45 (29.0%) patients reported grade 3 and above TRAEs. Significant differences in responsive disease rate were observed between iC cohort and induction immunochemotherapy (iIC) cohort [objective response rate: iIC: 63.2% vs. iC: 47.7%, p = 0.004; pathological complete response: iIC: 22.4% vs. iC: 6.7%, p = 0.001). Higher anastomosis fistula rate was observed in the iC group (19.2%) compared with the iIC group (4%). Furthermore, Significantly higher event-free survival was observed in those who underwent conversion surgery.Conclusion: Our results supported that conversion surgery following immunochemotherapy is feasible and safe for patients with initially unresectable locally advanced ESCC. Both radiological and pathological response rates were significantly higher in the iIC cohort compared with those in the traditional iC cohort.

5 February 2024 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
SXShu-Han Xie
Shu-Han Xie
LYLi-Tao Yang
Li-Tao Yang
HZHai Zhang
Hai Zhang
ZTZi-Lu Tang
Zi-Lu Tang
ZLZhi-Wei Lin
Zhi-Wei Lin
MKMingqiang Kang
Mingqiang Kang
Purpose: The need for adjuvant therapy (AT) following neoadjuvant chemoimmunotherapy (nICT) and surgery in esophageal squamous cell cancer (ESCC) remains uncertain. This study aims to investigate whether AT offers additional benefits in terms of recurrence-free survival (RFS) for ESCC patients after nICT and surgery.Methods: Retrospective analysis was conducted between January 2019 and December 2022 from three centers. Eligible patients were divided into two groups: the AT group and the non-AT group. Survival analyses comparing different modalities of AT (including adjuvant chemotherapy and adjuvant chemoimmunotherapy) with non-AT were performed. The primary endpoint was RFS. Propensity score matching(PSM) was used to mitigate inter-group patient heterogeneity. Kaplan-Meier survival curves and Cox regression analysis were employed for recurrence-free survival analysis.Results: A total of 155 nICT patients were included, with 26 patients experiencing recurrence. According to Cox analysis, receipt of adjuvant therapy emerged as an independent risk factor(HR:2.621, 95%CI:[1.089,6.310], P=0.032), and there was statistically significant difference in the Kaplan-Meier survival curves between non-AT and receipt of AT in matched pairs (p=0.026). Stratified analysis revealed AT bring no survival benefit to patients with pathological complete response(p= 0.149) and residual tumor cell(p=0.062). Subgroup analysis showed no significant difference in recurrence-free survival between non-AT and adjuvant chemoimmunotherapy patients(P=0.108). However, patients receiving adjuvant chemotherapy exhibited poorer recurrence survival compared to non-AT patients (p= 0.016).Conclusion: In terms of recurrence-free survival for ESCC patients after nICT and surgery, the necessity of adjuvant therapy especially the adjuvant chemotherapy, can be mitigated.

8 March 2025 in Journal of Biomedical Science
Verified
Journal Article
Open access
PDF file
Gilbert LeeGilbert Lee
Gilbert Lee
JHJustin Bo-Kai Hsu
Justin Bo-Kai Hsu
YCYu-Wei Chang
Yu-Wei Chang
LHLi-Chun Hsieh
Li-Chun Hsieh
YLYi-Tien Li
Yi-Tien Li
CCCheng-Yu Chen
Cheng-Yu Chen
Background: Glioblastoma multiforme (GBM) is an aggressive brain tumor with chemoresistant, immunosuppressive, and invasive properties. Despite standard therapies, including surgery, radiotherapy, and temozolomide (TMZ) chemotherapy, tumors inevitably recur in the peritumoral region. Targeting GBM-mediated immunosuppressive and invasive properties is a promising strategy to improve clinical outcomes. Methods: We utilized clinical and genomic data from the Taiwan GBM cohort and The Cancer Genome Atlas (TCGA) to analyze RNA sequencing data from patient tumor samples, determining the association of interleukin-19 (Il-19) expression with survival and immunosuppressive activity. Gene set enrichment analysis (GSEA) was performed to assess the relationship between the enrichment levels of immune subsets and Il-19 expression level, and Ingenuity Pathway Analysis (IPA) was used to predict immune responses. Cytokine array and single-cell RNA sequencing were used to examine the effects of IL-19 blockade on tumor immune microenvironment, including tumor-infiltrating leukocyte profiles, differentiation and immunosuppressive genes expression in tumor associated macrophages (TAM). CRISPR Il-19 −/− cell lines and Il-19 −/− mice were used to examine the role of IL-19 in tumor invasion and M2-like macrophage-mediated immunosuppression. Additionally, we developed novel cholesterol-polyethylene glycol-superparamagnetic iron oxide-IL-19 antibody nanoparticles (CHOL-PEG-SPIO-IL-19), characterized them using dynamic light scattering and transmission electron microscopy, Fourier-Transform Infrared spectroscopy, prussian blue assay, and conducted in vivo magnetic resonance imaging (MRI) in a human glioblastoma stem cell-derived GBM animal model. Result: Genomic screening and IPA analysis identified IL-19 as a predicted immunosuppressive cytokine in the peritumoral region, associated with poor survival in patients with GBM. Blocking IL-19 significantly inhibited tumor progression of both TMZ-sensitive (TMZ-S) and TMZ-resistant (TMZ-R) GBM-bearing mice, and modulated the immune response within the GBM microenvironment. Single-cell transcriptome analysis reveal that IL-19 antibody treatment led to a marked increase in dendritic cells and monocyte/macrophage subsets associated with interferon-gamma signaling pathways. IL-19 blockade promoted T cell activation and reprogrammed tumor-associated macrophages toward weakened pro-tumoral phenotypes with reduced Arginase 1 expression. Il19 −/− M2-like bone marrow-derived macrophages with lower Arginase 1 level lost their ability to suppress CD8 T cell activation. These findings indicated that IL-19 suppression limits TAM-mediated immune suppression. Molecular studies revealed that IL-19 promotes TMZ-resistant GBM cell migration and invasion through a novel IL-19/WISP1 signaling pathway. For clinical translation, we developed a novel CHOL-PEG-SPIO-IL-19 nanoparticles to target IL-19 expression in glioblastoma tissue. MRI imaging demonstrated enhanced targeting efficiency in brain tumors, with in vivo studies showing prominent hypointense areas in T2*-weighted MRI scans of tumor-bearing mice injected with CHOL-PEG-SPIO-IL-19, highlighting nanoparticle presence in IL-19-expressing regions. Prussian blue staining further confirmed the localization of these nanoparticles in tumor tissues, verifying their potential as a diagnostic tool for detecting IL-19 expression in glioblastoma. This system offers a theranostic approach, integrating diagnostic imaging and targeted therapy for IL-19-expressing GBM. Conclusion: IL-19 is a promising theranostic target for reversing immunosuppression and restricting the invasive activity of chemoresistant GBM cells. Graphical

5 March 2024 in Asian Journal of Surgery
Verified
Journal Article
Open access
JKJunli Ke
Junli Ke
YXYujie Xie
Yujie Xie
SHShenyang Huang
Shenyang Huang
WWWei Wang
Wei Wang
ZZZhengang Zhao
Zhengang Zhao
WLWanli Lin
Wanli Lin
Surgery after neoadjuvant chemoradiotherapy remains the gold standard for the treatment of resectable esophageal cancer (EC); however, chemoradiotherapy without surgery has been recommended in specific cases. The aim of this meta-analysis is to analyse the survival between surgeries after neoadjuvant chemoradiotherapy compared with definitive chemoradiotherapy in order to provide a theoretical basis for clinically individualised differential treatment. We conducted an initial search of MEDLINE (PubMed), the Cochrane Library, and Embase for English-only articles that compared treatment regimens and provided survival data. According to the final I2 value of the two survival indicators, the random effect model or fixed effect model was used to calculate the overall hazard ratio (HR) and 95% confidence intervals (CI). Cochrane's Q test was used to judge the heterogeneity of the studies, and a funnel plot was used to evaluate for publication bias. A sensitivity analysis was performed to verify the stability of the included studies. A total of 38 studies involving 29161 patients (neoadjuvant therapy: 15401, definitive chemoradiotherapy: 13760) were included in the analysis. The final pooled results (HR = 0.74, 95% CI: 0.67-0.82) showed a statistically significant increase in overall survival with neoadjuvant chemoradiotherapy plus surgery compared with definitive chemoradiotherapy. Subgroup analyses were performed to determine the effects of heterogeneity, additional treatment regimens, study types, and geographic regions, as well as histologic differences, complications, and recurrence, on the overall results. For people with esophageal cancer that can be removed, neoadjuvant chemoradiotherapy combined with surgery improves survival compared to definitive chemoradiotherapy. However, more research is needed to confirm these results and help doctors make decisions about treatment.

1 March 2023 in Journal of Thoracic Disease
Verified
Journal Article
Open access
PDF file
HZHai Zhang
Hai Zhang
ZZZhenyang Zhang
Zhenyang Zhang
LYLitao Yang
Litao Yang
BWBomeng Wu
Bomeng Wu
YCYing Chen
Ying Chen
JLJiangbo Lin
Jiangbo Lin
Original Article Perioperative outcomes of neoadjuvant immunotherapy plus chemotherapy and neoadjuvant chemoradiotherapy in the treatment of locally advanced esophageal squamous cell carcinoma: a retrospective comparative cohort study Hai Zhang, Zhenyang Zhang, Litao Yang, Bomeng Wu, Ying Chen, Haiquan He, Cui Li, Wanli Lin, Jiangbo Lin

8 December 2025 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
HZHai Zhang
Hai Zhang
ZDZicheng Dai
Zicheng Dai
BWBei Wang
Bei Wang
BWBomeng Wu
Bomeng Wu
JLJiangbo Lin
Jiangbo Lin
WLWanli Lin
Wanli Lin
Background: This study aimed to evaluate the safety and efficacy of neoadjuvant immunochemotherapy (nICT) compared to those of neoadjuvant chemoradiotherapy (nCRT) and neoadjuvant chemotherapy (nCT) in patients with locally advanced resectable esophageal squamous cell carcinoma (ESCC). Methods: Patients with locally advanced resectable ESCC undergoing neoadjuvant therapy followed by minimally invasive McKeown esophagectomy (MIE) between January 1, 2019, and January 1, 2022, were categorized into the nCT, nCRT, and nICT groups. Inverse probability of treatment weighting (IPTW) was used to balance the 13 baseline covariates across the groups. Post-IPTW comparisons included adverse events, surgical outcomes, pathologic complete response (PCR), tumor downstaging, and perioperative complications. Results: A total of 437 patients were enrolled (nICT = 218, nCRT = 78, nCT = 141). After propensity score matching (PSM), 78 patients were included in each group. During neoadjuvant therapy, the incidence of leukopenia was significantly higher in the nCRT (33.33%) and nICT (23.08%) groups than in the nCT (10.26%), p < 0.05. Neutropenia rates followed a similar trend (nCRT: 19.23%; nICT: 17.95%; nCT: 2.56%, p < 0.05). Immune-related dermatitis occurred in 10.26% of patients with nICT. Operative duration was significantly longer with nCRT (347.8 ± 80.8 min) than nCT (325.1 ± 52.6 min; p < 0.05). The tumor-downstaging efficacy was ranked as follows: nICT > nCRT > nCT ( p < 0.05). Lymph node dissection:Yields: nCRT (26 ± 11) < nICT (36 ± 14) and nCT (35 ± 12) ( p < 0.05),Stations: nICT (13 ± 4) > nCRT (9 ± 2) and nCT (11 ± 2) ( p < 0.05). The PCR rates were 34.61% (nCRT), 26.92% (nICT), and 5.13% (nCT), respectively ( p < 0.05). Postoperative 30-day mortality occurred in three nCRT and one nCT patients. Postoperative arrhythmia incidence was highest with nICT (12.82%), intermediate with nCT (5.13%), and absent with nCRT (0.00%). Conclusion: For locally advanced resectable ESCC, nCRT requires vigilant management because of its association with grade 3 treatment-related adverse events (AEs). While nICT demonstrates a lower incidence of severe (grade ≥ 3) non-immune toxicities compared to nCRT, supporting its controllable safety. nCRT achieved superior PCR rates versus nICT/nCT, but nICT showed greater nodal (N) downstaging efficacy. Conversely, nCRT provided enhanced primary tumor (T) control.